Aripiprazole Tablet
Product Images NDC 43598-558

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 43598-558). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy�s Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Aripiprazole Structure)

Chemical structure of Aripiprazole, showing its molecular arrangement including dichlorophenyl, piperazine, and quinolinone components.*

FDA Label Image

Figure-1.jpg (Aripiprazole Figure1)

A pharmacokinetic effect chart illustrating the fold change and 90% confidence intervals of Aripiprazole exposure (AUC and Cmax) when co-administered with various drugs. The chart compares changes relative to reference (without interacting drug) for CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blockers (famotidine), and other drugs including valproate, lithium, and lorazepam.*

FDA Label Image

Figure-2.jpg (Aripiprazole Figure2)

A pharmacokinetic chart showing the effect of various other drugs on aripiprazole by plotting dehydro-aripiprazole fold change with 90% confidence intervals. The x-axis represents change relative to reference (without interacting drug) and lists different inhibitors, inducers, and other drugs. The y-axis shows pharmacokinetic parameters AUC and Cmax.*

FDA Label Image

Figure-3.jpg (Aripiprazole Figure3)

A chart titled 'Effect of Aripiprazole on Other Drugs' showing fold changes with 90% confidence intervals for various drugs and pharmacokinetic parameters. The horizontal axis represents change relative to a reference without interacting drug, ranging from 0.5 to 3. Drugs listed include dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. Measurements include PK parameters such as DM/DPR, AUC, Cmax, and INR.*

FDA Label Image

Figure-4.jpg (Aripiprazole Figure4)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing fold changes in AUC and Cmax relative to reference values for different special populations. Categories include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with data points and confidence intervals displayed as horizontal bars on a scale from 0.5 to 3.0.*

FDA Label Image

Figure-5.jpg (Aripiprazole Figure5)

A chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing pharmacokinetic comparisons of Aripiprazole based on factors including CYP2D6 metabolizer status, gender, age groups, hepatic and renal impairment. The x-axis represents change relative to reference, while the y-axis lists factors with AUC and Cmax parameters. Data points with confidence intervals are plotted to visualize fold changes.*

FDA Label Image

Figure-6.jpg (Aripiprazole Figure6)

A line graph comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization up to 182, and the y-axis shows the proportion with relapse. Aripiprazole is represented by a blue solid line and placebo by a red dashed line. Below the graph, a table indicates the number of subjects at risk for both groups at various time points.*

FDA Label Image

Figure 7 (Aripiprazole Figure7)

A Kaplan-Meier survival curve showing the proportion of subjects with relapse over time (days from randomization) comparing Aripiprazole and placebo groups. The graph includes the number of subjects at risk at various time points for both groups, with Aripiprazole indicated by a solid blue line and placebo by a dashed red line.*

FDA Label Image

Figure 8 (Aripiprazole Figure8)

A line graph comparing the proportion of subjects with relapse over time between Aripiprazole and placebo groups. The X-axis represents days from randomization up to 364 days, and the Y-axis shows the proportion with relapse ranging from 0.0 to 1.0. Two lines are shown: a solid blue line for Aripiprazole and a dashed red line for placebo, with placebo showing a higher relapse proportion. The number of subjects at risk is tabulated below the X-axis for both groups at various time points.*

FDA Label Image

2mg-30 (Aripiprazole Label2)

Label for Aripiprazole Tablets, USP 2 mg oral tablets by Dr. Reddy's Laboratories Inc. The package contains 30 tablets and is marked Rx Only. The label includes storage instructions and states the tablet contains 2 mg of aripiprazole, USP. It also emphasizes dispensing the accompanying Medication Guide.*

FDA Label Image

5mg-30 (Aripiprazole Label4)

Label for Aripiprazole Tablets, USP 5 mg oral tablets by Dr. Reddy's Laboratories Inc. The label states the NDC 43598-555-30, prescription-only status, package of 30 tablets, and includes storage instructions. It features branding and a barcode with revision date 07/18.*

FDA Label Image

10mg-30 (Aripiprazole Label6)

Label for Aripiprazole Tablets, USP 10 mg oral tablets, supplied in a package of 30 tablets. The label includes dosing instructions directing pharmacists to dispense the Medication Guide, storage conditions, and manufacturer information for Dr. Reddy's Laboratories Inc. It features the Dr. Reddy's logo and a barcode, along with the phrase 'NO VARNISH' on the right side.*

FDA Label Image

15mg-30 (Aripiprazole Label8)

Aripiprazole Tablets USP 15 mg oral tablet bottle label showing NDC 43598-557-30. The label includes instructions for pharmacists to dispense an accompanying Medication Guide with 30 tablets per bottle. The product is labeled by Dr. Reddy's Laboratories Inc. Storage temperature guidance and prescription-only status are also displayed. A barcode and "NO VARNISH" are visible on the label.*

FDA Label Image

20mg-30 (Aripiprazole Label10)

Label for Aripiprazole Tablets USP 20 mg by Dr. Reddy's Laboratories Inc. The label indicates oral tablet dosage form with a package size of 30 tablets. It includes storage instructions, a note for pharmacists to dispense an accompanying medication guide, and the Rx only designation. The label also shows the NDC number 43598-558-30 and a barcode.*

FDA Label Image

30mg-30 (Aripiprazole Label12)

Label for Aripiprazole Tablets USP, 30 mg strength, oral tablets packaged in a bottle of 30 tablets. The label includes dispensing instructions for pharmacists, storage conditions (20° to 25°C, excursions permitted between 15° to 30°C), and manufacturer information, Dr. Reddy's Laboratories Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.